Putnam Investments LLC raised its holdings in Edwards Lifesciences Corp (NYSE:EW) by 7.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 68,479 shares of the medical research company’s stock after purchasing an additional 4,723 shares during the period. Putnam Investments LLC’s holdings in Edwards Lifesciences were worth $9,969,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Voya Investment Management LLC increased its position in Edwards Lifesciences by 47.9% in the second quarter. Voya Investment Management LLC now owns 911,238 shares of the medical research company’s stock worth $132,649,000 after buying an additional 295,113 shares during the period. OppenheimerFunds Inc. grew its stake in shares of Edwards Lifesciences by 5.7% in the second quarter. OppenheimerFunds Inc. now owns 161,270 shares of the medical research company’s stock worth $23,476,000 after purchasing an additional 8,684 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Edwards Lifesciences by 3.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 794,667 shares of the medical research company’s stock worth $115,680,000 after purchasing an additional 26,346 shares in the last quarter. Summit Global Investments bought a new position in shares of Edwards Lifesciences in the second quarter worth $2,923,000. Finally, Highstreet Asset Management Inc. grew its stake in shares of Edwards Lifesciences by 14.3% in the second quarter. Highstreet Asset Management Inc. now owns 5,959 shares of the medical research company’s stock worth $867,000 after purchasing an additional 744 shares in the last quarter. 82.10% of the stock is currently owned by institutional investors.

Several research analysts have recently issued reports on EW shares. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research note on Saturday, July 14th. Guggenheim reiterated a “buy” rating and issued a $170.00 price target on shares of Edwards Lifesciences in a research report on Friday, July 27th. Jefferies Financial Group reiterated a “buy” rating and issued a $168.00 price target on shares of Edwards Lifesciences in a research report on Friday, July 27th. SunTrust Banks decreased their price target on Edwards Lifesciences to $170.00 and set a “buy” rating for the company in a research report on Friday, August 10th. Finally, ValuEngine raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fifteen have given a buy rating to the company. Edwards Lifesciences presently has a consensus rating of “Buy” and a consensus target price of $155.30.

Shares of EW traded up $3.62 during midday trading on Friday, reaching $143.39. 2,098,946 shares of the stock were exchanged, compared to its average volume of 1,375,395. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.86 and a quick ratio of 1.47. The company has a market capitalization of $36.45 billion, a PE ratio of 37.73, a price-to-earnings-growth ratio of 2.41 and a beta of 0.56. Edwards Lifesciences Corp has a 12-month low of $100.20 and a 12-month high of $175.00.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 EPS for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.11. The business had revenue of $972.00 million for the quarter, compared to analyst estimates of $968.32 million. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 19.59%. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.08 EPS. On average, equities research analysts expect that Edwards Lifesciences Corp will post 4.67 earnings per share for the current fiscal year.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction that occurred on Tuesday, July 31st. The stock was sold at an average price of $141.86, for a total value of $4,667,194.00. Following the sale, the chief executive officer now owns 43,126 shares of the company’s stock, valued at approximately $6,117,854.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 10th. The shares were sold at an average price of $147.50, for a total value of $811,250.00. Following the completion of the sale, the vice president now directly owns 25,490 shares in the company, valued at approximately $3,759,775. The disclosure for this sale can be found here. In the last three months, insiders have sold 158,811 shares of company stock worth $22,738,863. 1.84% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Read More: What is Considered a Good Return on Equity (ROE)?

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.